Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 8;6:23. doi: 10.1038/s41541-021-00284-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — The first cluster from the left shows titers for binding to NiV-sG antigen on the day of the challenge, d0. All other clusters show titers for binding to vaccine subunit HeV-sG antigen at the day of the challenge, d0, and at days 3, 6, 8, 10, 14, 21, and 28 post challenge. The bars in each cluster, numbered from 1 to 6, show the average titer and the standard deviation for sera samples from Study 1 AGM groups: bars 1—control group in HeV challenge (these bars show the titers for the single survived AGM-1-C1-2); bars 2—control group in NiV challenge; bars 3—single-dose group in HeV challenge; bars 4—single-dose group in NiV challenge; bars 5—prime/boost group in HeV challenge; and bars 6—prime/boost group in NiV challenge. Error bars show standard deviations.